Senti Biosciences is trading at $0.53 (14% down) after announcing a definitive agreement to sell substantially all of its existing business and pipeline to an affiliate of its largest shareholder, Celadon Partners.
- The company reported preliminary cash of just $6.5 million as of June 30, 2026, signaling significant financial distress.
- Senti is effectively pivoting to a much smaller, IP-focused structure, creating substantial uncertainty regarding its future operations and long-term value.